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Sir,
We thank Drs Bonetti and Manfrin for sharing the results of
their screening programme in Verona with us. The similarity in the
designs of our respective programmes affords a valuable learning
opportunity.
Based on their experience with 388 circumscribed 3B screen-
detected mass lesions, Drs Bonetti and Manfrin confirm our data
regarding the value of fine-needle aspiration biopsy as a first-line
diagnostic modality for this specific category of lesions. They also
subscribe to a tiered approach for the assessment of these lesions,
reserving core biopsies for cases other than benign cytology.
The proportion of malignancies presenting as 3B masses in the
Verona Programme is reported as 4.9%. Given the smaller
numbers in their series, 388 cases compared with 1183 in
the South Australian series, these findings are broadly
comparable with the 8.3% rate of malignant diagnoses in our data
(Farshid et al, 2008).
However, our recall rate is 6.7% for the first round and 2.2% for
subsequent rounds, whereas they have a recall rate of 10.9% for the
first round of screening and 5.4% for subsequent rounds. They
point out that these rates are ‘not acceptable according to the
European guidelines’ and go on to suggest that because a survival
benefit has not been specifically established for cancers that
present as circumscribed masses, perhaps ‘assessment of 3B
lesions should be discouraged’. They then express likely reluctance
in adopting this approach by clinicians, their claims managers and
the clients themselves.
In essence, Drs Bonetti and Manfrin highlight the challenging
balance in achieving acceptably low recall rates for breast cancer
screening programmes while demonstrating a public health benefit
from the exercise.
As highlighted in Table 1, there is some variation in recall rates
deemed acceptable by various screening programmes and within
each jurisdiction observed recall rates may well exceed the desired
thresholds, sometimes by significant margins.
As 3B masses are common and mostly represent benign lesions,
it is true that deferring the assessment of these lesions by adopting
the policy of surveillance will reduce recall rates. However, 8.3% of
these women whose lesions are indeed malignant will be denied the
opportunity for early diagnosis. We therefore do not support this
approach.
Quite apart from the public health and medical objections to the
watchful waiting approach is the irony that this strategy will not
solve the accreditation problems of programmes significantly. This
is because programmes adopting this policy will potentially have to
deal with substantially increased numbers of interval cancers, so
that as is often the case, a measure undertaken to rectify one
performance index results in the deterioration of another statistic.
In the light of the low proportion of high-grade cancers in their
cohort, our colleagues in Verona raise the second issue of a
survival benefit associated with the detection of cancers that
present as 3B lesions. As a result of multiple randomised clinical
trials, case–control series, meta-analyses and expert reviews
undertaken by the IARC, there is now a high level of concordance
that screening mammography is effective in reducing mortality
from breast cancer. The magnitude of this effect is estimated to be
in the region of 25–35% (WHO and IARC, 2002). This mortality
reduction is achieved even though the majority of screen-detected
cancers in these trials were of grade I or II, and indeed data from
the Swedish two county trial demonstrate that it is predominantly
the effects of small tumour diameter and node negativity that
substantially improve survival expectations (Tabar et al, 2000). A
recent case-controlled study evaluating our screening programme
has demonstrated a 41% survival advantage for women who are
regular participants (Roder et al, 2008). The breakdown of tumour
grade in our programme is that 43.2% are grade I, 42.6% grade II
and 14.3% grade III (unpublished data).
Drs Bonetti and Manfrin correctly point out that there is no
definite proof that the detection of cancers that present as 3B
masses will result in a reduction in breast cancer mortality. Such
evidence is unlikely to be forthcoming in the form of randomised
controlled trial data. The trials having proven the efficacy of
Table 1 Acceptable recall rates for screening mammography in different
programmes
Programme
First screening
round
Subsequent
screening rounds
Australian National Accreditation
Standards (2004)
o10% o5%
United Kingdom (NHSBSP, 2005) o10% o7%
European guidelines (2006) o7% o5% *Correspondence: Dr G Farshid; E-mail: gelareh.farshid@health.sa.gov.au
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each different radiologic presentation of breast cancer.
In our view, the importance of 3B mass lesions is two-fold:
first, 8.3% of these lesions represent malignancies, whose detection
and management will provide valuable opportunities for inter-
rupting the natural history of some breast cancers. Second,
because 3B masses are common and mostly represent benign
lesions, particular care is required to reduce the physical and
psychologic morbidity associated with their assessment. Our
preferred approach is to utilise the least invasive methods available
for their assessment, so that the cancers may be diagnosed
and women with benign lesions may be reassured and return for
re-screening at the correct interval.
Our contribution in this work has been the substantiation of
the fact that a tiered approach using fine-needle aspiration
biopsy and core biopsy achieves these outcomes successfully.
A final observation is that this approach may be more cost-
effective than short-term recall and repeat imaging.
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